Market Capitalization (Millions $) |
1 |
Shares
Outstanding (Millions) |
3 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-48 |
Cash Flow (TTM) (Millions $) |
-25 |
Capital Exp. (TTM) (Millions $) |
0 |
Axcella Health Inc
Axcella Health Inc is a biotechnology company that is focused on discovering and developing novel, multi-targeted interventions to improve the lives of patients with complex diseases and conditions. The company uses its proprietary platform, called EMMET, to build a deep understanding of biology and develop clinical candidates.
Axcella is primarily focused on the development of endogenous metabolic modulators (EMMs), which are naturally occurring molecules that help regulate metabolism. These EMMs have the potential to address multiple underlying pathways associated with various diseases and conditions.
The company's pipeline includes candidates for liver, muscle, and blood disorders, as well as oncology. Axcella is dedicated to advancing these candidates through clinical studies to generate data and obtain regulatory approvals.
Axcella Health Inc combines its innovative science with a patient-centric approach, aiming to bring safe and effective treatments to those in need. The company's mission is to transform the lives of patients through the development of novel therapies that leverage the power of the body's own systems.
Company Address: P.O. Box 1270 Littleton 1460 MA
Company Phone Number: 320-2200 Stock Exchange / Ticker: NASDAQ AXLA
AXLA is expected to report next financial results on March 29, 2024. |
|
|